PD27-06 SIMVASTATIN AND METFORMIN: A DEADLY COMBINATION FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

PSA � 25%, PSMA � 18%, and hK2 � 33%. In the sipuleucel-T arm of IMPACT, IgG response against PSA was positively correlated with improved OS (HR¼0.41; 95% CI, 0.22e0.78; p 33 months) in pts with IgG response to PSA (n¼35), compared to 22 months in pts with no IgG response to PSA (n¼105), and 21.4 months for the control group. IgG responses to PSMA and hK2 were not correlated with OS. CONCLUSIONS: The immune response to sipuleucel-T adapts over time through antigen spreading to target multiple prostate antigens. Sipuleucel-T-induced IgG responses against PSA were predictive of OS and may be a potential biomarker of treatment benefit. These data may identify pharmacodynamic biomarkers of clinical outcome after treatment with sipuleucel-T. Source of Funding: Dendreon Corporation